发明公开
- 专利标题: Drug carrier and drug carrier kit for inhibiting fibrosis
- 专利标题(中): 用于抑制纤维化的药物载体和药物载体试剂盒
-
申请号: EP13193438.2申请日: 2005-12-22
-
公开(公告)号: EP2730277A2公开(公告)日: 2014-05-14
- 发明人: Niitsu, Yoshiro , Kato, Junji , Sato, Yasushi
- 申请人: NITTO DENKO CORPORATION
- 申请人地址: 1-1-2, Shimohozumi Ibaraki-shi, Osaka 567-8680 JP
- 专利权人: NITTO DENKO CORPORATION
- 当前专利权人: NITTO DENKO CORPORATION
- 当前专利权人地址: 1-1-2, Shimohozumi Ibaraki-shi, Osaka 567-8680 JP
- 代理机构: HOFFMANN EITLE
- 优先权: JP2004382791 20041222
- 主分类号: A61K9/107
- IPC分类号: A61K9/107 ; A61K9/127 ; A61K31/7088 ; A61K31/07 ; A61K45/06 ; A61K9/50 ; A61K9/51 ; A61P1/16 ; A61P1/18 ; A61P43/00
摘要:
A stellate cell-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, a stellate cell-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of stellate cells, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.
公开/授权文献
- EP2730277B1 Drug carrier and drug carrier kit for inhibiting fibrosis 公开/授权日:2020-03-11
信息查询